FHA
RPRX icon

Flagship Harbor Advisors’s Royalty Pharma RPRX Stock Holding History

Flagship Harbor Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,550
Closed -$253K – 1871
2025
Q4 		$253K Buy
6,550
+374
+6% +$14.3K 0.01% 609
2025
Q3 		$218K Buy
+6,176
New +$224K 0.01% 746

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Flagship Harbor Advisors's RPRX Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 6,550 shares — an estimated $253K sold.

Flagship Harbor Advisors first reported a position in RPRX in Q3 2025 and held it in 2 quarters. The position peaked at $253K in Q4 2025. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 6,550 Royalty Pharma shares in Q1 2026, an estimated $253K.
  • Flagship Harbor Advisors first reported a position in Royalty Pharma in Q3 2025 and held it in 2 quarters.
  • Flagship Harbor Advisors's Royalty Pharma position peaked at $253K in Q4 2025.
  • 590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.